Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth

Kainova champions scientific agility, bold ambition, and unity of purpose

Montreal, Canada; Strasbourg, France; Boston, USA: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new name and brand reflect the Company’s clinical momentum, global focus, and readiness for the next chapter of strategic growth, anchored by a mature pipeline of G Protein-Coupled Receptor (GPCR)-modulating therapies.

The name “Kainova” combines “Kairos,” the opportune or decisive moment, and “Nova,” symbolizing innovation and renewal. It embodies the Company’s transformation and ambition, reflecting its drive to innovate, determination to deliver, and commitment to therapies that truly transform lives. Built on a strong scientific foundation, a proprietary discovery platform, an integrated development approach, and experienced leadership, the new brand underscores Kainova’s commitment to clinical excellence, value creation, and lasting impact.

“The rebrand is not a break from our scientific or strategic roots,” said Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics. “It is the clearer expression of who we are today and the impact we strive to deliver for patients. It highlights a continuation between our past successes and the growth path we envision for the future. Above all, Kainova Therapeutics embodies our belief that better is always possible.”

Leveraging decades of scientific and medical expertise and a proven track record of collaborations with pharma, Kainova is advancing innovative, clinically differentiated therapies designed to unlock the untapped potential of GPCRs. Kainova employs a fully integrated, forward-thinking approach to GPCR drug discovery and smart development, moving programs efficiently from concept to clinic and strengthening its position as a leader in the field. The Company’s leading programs include DT-7012, a Treg-depleting anti-CCR8 antibody with competitive properties in Phase I/II trials for solid tumors, DT-9046, a first-in-modality, pre-IND biased PAR2 antagonist in inflammation, and DT-9081, a Phase II-ready EP4 receptor antagonist for solid tumors.

With operations in North America, France, and Australia, and a growing clinical pipeline, Kainova is entering its next chapter, shaping the future of GPCR-modulating therapies, transforming lives, and expanding its global reach.

The Kainova leadership will be in San Francisco during the J.P. Morgan Healthcare Conference, January 12–15, 2026, and welcomes the opportunity to share how the Company is advancing its clinical pipeline of GPCR-modulating therapies to create a meaningful impact for patients.

###

Contact
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens
+44 (0) 203 882 9621
kainova@optimumcomms.com

For French-speaking media:
communication@kainovatx.com